FOXO4-DRI regulatory status
Current status of FOXO4-DRI in the United States: Unscheduled. In sport: WADA prohibited. Details, sources, and the dated timeline follow.
By the PeptideAgent Editorial Team. Draft, pending editorial review. Last verified
What is the current status of FOXO4-DRI?
Regulatory: UnscheduledWADA: WADA prohibitedVerified: Verified Sep 22, 2026
- FDA and compounding
- FOXO4-DRI is not an FDA approved drug and PeptideAgent has not identified it on the FDA 503A bulks nomination lists or in any Pharmacy Compounding Advisory Committee review. Without a listing, a 503A pharmacy cannot lawfully compound it as a bulk substance. It is not eligible for 503B outsourcing. Products sold under this name are not lawful for human use and, because the peptide is long and made entirely of D-amino acids, are expensive and difficult to verify.
- WADA
- WADA prohibited
- Access path
- Not legally available: no approved product, no clinical trials open to the public, and no 503A bulks listing.
- Products labeled research use only are not lawful for human use and are not verified for identity or purity.
Full FOXO4-DRI page: evidence, dosing in the literature, and sources
How has the status of FOXO4-DRI changed over time?
No dated regulatory event has been recorded for FOXO4-DRI. That usually means no FDA, PCAC, Federal Register, or WADA action has named it specifically. Category-wide actions are listed on the tracker hub.
Sources
Numbered citations in the answers above point here, followed by the regulatory sources on record for FOXO4-DRI and the source of each dated event.
- [1]FDA: Bulk drug substances used in compounding under section 503A of the FD&C Act (links to the Category 1, 2, and 3 lists and the bulks list)FDA, 2026
- [2]FDA Pharmacy Compounding Advisory Committee meetings (July 2026 meeting on peptide nominations)FDA, 2026
- [3]WADA Prohibited List, section S0 non-approved substancesWADA, 2026